We’re excited to announce that XDEMVY™ is now approved for Demodex blepharitis. Formerly known as TP-03, XDEMVY is the first and only FDA-approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis.
Important Safety Information:
Most common side effects: Most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.
Please see full Important Safety Information at XDEMVY.com.
Please reach out to us using the form below.
"*" indicates required fields